Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Expert Rev Pharmacoecon Outcomes Res ; 24(5): 687-695, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38716801

RESUMO

BACKGROUND: The treatment of chronic hepatitis C virus (HCV) infection using directly acting antivirals was recently adopted in the treatment guidelines of Zimbabwe. The objectives of this study were to design a simplified model of HCV care and estimate the cost of screening and treatment of hepatitis C infection at a tertiary hospital in Zimbabwe. METHODS: We developed a model of care for HCV using WHO 2018 guidelines for the treatment of HCV infection and expert opinion. We then performed a micro-costing to estimate the costs of implementing the model of care from the healthcare sector perspective. Deterministic and probabilistic sensitivity analyses were performed to explore the impact of uncertainty in input parameters on the estimated total cost of care. RESULTS: The total cost of screening and treatment was estimated to be US$2448 (SD=$290) per patient over a 12-week treatment duration using sofosbuvir/velpatasvir. The cost of directly acting antivirals contributed 57.5% to the total cost of care. The second largest cost driver was the cost of diagnosis, US$819, contributing 34.6% to the total cost of care. CONCLUSION: Screening and treatment of HCV-infected individuals using directly acting antivirals at a tertiary hospital in Zimbabwe may require substantial financial resources.


Assuntos
Antivirais , Custos de Cuidados de Saúde , Hepatite C Crônica , Programas de Rastreamento , Centros de Atenção Terciária , Humanos , Zimbábue , Centros de Atenção Terciária/economia , Antivirais/economia , Antivirais/administração & dosagem , Antivirais/uso terapêutico , Programas de Rastreamento/economia , Programas de Rastreamento/métodos , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/economia , Hepatite C Crônica/diagnóstico , Custos de Cuidados de Saúde/estatística & dados numéricos , Guias de Prática Clínica como Assunto , Custos e Análise de Custo , Modelos Econômicos
2.
Int J Technol Assess Health Care ; 40(1): e27, 2024 Apr 29.
Artigo em Inglês | MEDLINE | ID: mdl-38679461

RESUMO

OBJECTIVES: Systematic priority setting is necessary for achieving high-quality healthcare using limited resources in low- and middle-income countries. Health technology assessment (HTA) is a tool that can be used for systematic priority setting. The objective of this study was to conduct a stakeholder and situational analysis of HTA in Zimbabwe. METHODS: We identified and analyzed stakeholders using the International Decision Support Initiative checklist. The identified stakeholders were invited to an HTA workshop convened at the University of Zimbabwe. We used an existing HTA situational analysis questionnaire to ask for participants' views on the need, demand, and supply of HTA. A follow-up survey was done among representatives of stakeholder organizations that failed to attend the workshop. We reviewed two health policy documents relevant to the HTA. Qualitative data from the survey and document review were analyzed using thematic analysis. RESULTS: Forty-eight organizations were identified as stakeholders for HTA in Zimbabwe. A total of 41 respondents from these stakeholder organizations participated in the survey. Respondents highlighted that the HTA was needed for transparent decision making. The demand for HTA-related evidence was high except for the health economic and ethics dimensions, perhaps reflecting a lack of awareness. Ministry of Health was listed as a major supplier of HTA data. CONCLUSIONS: There is no formal HTA agency in the Zimbabwe healthcare system. Various institutions make decisions on prioritization, procurement, and coverage of health services. The activities undertaken by these organizations provide context for the institutionalization of HTA in Zimbabwe.


Assuntos
Participação dos Interessados , Avaliação da Tecnologia Biomédica , Zimbábue , Avaliação da Tecnologia Biomédica/organização & administração , Humanos , Tomada de Decisões , Prioridades em Saúde , Política de Saúde
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA